SCHULMAN AMY W — SEC insider filings
SEC reporting owner CIK 1438226. 31 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2020-10-30 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 7 filings — 3,389,529 shares, $26,349,837 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 3 filings — 30,226 shares, $5,272,021 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: purchase of 909,090 shares @ $11.00 ($9,999,990) in Camp4 Therapeutics Corp, filed 2024-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 10% owner | 3 | 4 legs · 3,125,369 sh · $21,999,979 | — | 16 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 14 | 1 leg · 1,910 sh · $299,526 | 4 legs · 30,200 sh · $5,264,546 | 20 |
| SQZ Biotechnologies Co (SQZ) | Director, 10% owner | 7 | 4 legs · 253,700 sh · $4,040,367 | — | 25 |
| FRACTYL HEALTH, INC. (GUTS) | Director | 3 | 1 leg · 8,550 sh · $9,964 | — | 2 |
| Elevance Health, Inc. (ELV) | Director | 3 | — | 1 leg · 26 sh · $7,475 | 2 |
| Hudson Executive Investment Corp. II (HCII) | Director | 1 | — | — | 1 |
Insider filings — SCHULMAN AMY W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Purchase (P): 1,910 @ $156.82 | EDGAR |
| 2026-05-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 838 @ $0 · Grant/award (A): 1,802 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Elevance Health, Inc. (ELV) | Grant/award (A): 563 @ $0 | EDGAR |
| 2026-05-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 11,250 @ $70.20 · Option exercise (M): 11,250 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Elevance Health, Inc. (ELV) | Sale (S): 26 @ $287.50 | EDGAR |
| 2026-02-03 | 4 | Elevance Health, Inc. (ELV) | Grant/award (A): 218 @ $0 | EDGAR |
| 2025-09-11 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian | Purchase (P): 1,221,721 @ $1.53 · Purchase (P): 85,468 @ $1.53 | EDGAR |
| 2025-06-13 | 4 | FRACTYL HEALTH, INC. (GUTS) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | FRACTYL HEALTH, INC. (GUTS) | Purchase (P): 8,550 @ $1.17 | EDGAR |
| 2025-03-14 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 2,750 @ $131.21 · Option exercise (M): 2,750 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4/A | Camp4 Therapeutics Corp (CAMP) jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian | Conversion (C): 1,250,061 · Conversion (C): 87,448 · Conversion (C): 353,718 · Conversion (C): 24,745 · Purchase (P): 909,090 @ $11 · Conversion (C): 14,020,475 (derivative) · +3 more | EDGAR |
| 2024-10-15 | 4 | Camp4 Therapeutics Corp (CAMP) jointly with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C. | Conversion (C): 1,250,061 · Conversion (C): 87,448 · Conversion (C): 353,718 · Conversion (C): 24,745 · Purchase (P): 909,090 @ $11 · Conversion (C): 14,020,475 (derivative) · +3 more | EDGAR |
| 2024-06-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 8,500 @ $131.21 · Sale (S): 8,500 @ $240 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 30,000 @ $66.83 · Sale (S): 10,121 @ $148.21 · Sale (S): 11,516 @ $148.93 · Sale (S): 63 @ $149.76 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,228 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Fractyl Health, Inc. (GUTS) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | SQZ Biotechnologies Co (SQZ) | Grant/award (A): 39,875 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,454 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Option exercise (M): 136 @ $0 · Option exercise (M): 136 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | SQZ Biotechnologies Co (SQZ) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,153 (derivative) @ $0 | EDGAR |
| 2022-02-25 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 136 (derivative) @ $0 | EDGAR |
| 2021-12-23 | 4 | SQZ Biotechnologies Co (SQZ) | Option exercise (M): 10,091 @ $2.02 · Option exercise (M): 7,458 @ $4.59 · Option exercise (M): 6,581 @ $4.59 · Option exercise (M): 10,091 (derivative) @ $0 · Option exercise (M): 7,458 (derivative) @ $0 · Option exercise (M): 6,581 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | SQZ Biotechnologies Co (SQZ) | Purchase (P): 1,850 @ $10.88 · Purchase (P): 1,850 @ $10.94 | EDGAR |
| 2021-10-29 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 1,814 (derivative) @ $0 | EDGAR |
| 2021-07-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,032 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | SQZ Biotechnologies Co (SQZ) | Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2021-04-14 | 4 | Hudson Executive Investment Corp. II (HCII) | Purchase (P): 20,000 (derivative) @ $0.00 | EDGAR |
| 2020-11-03 | 4 | SQZ Biotechnologies Co (SQZ) | Conversion (C): 22,204 · Conversion (C): 161,994 · Conversion (C): 2,315,652 · Conversion (C): 275,860 · Purchase (P): 16,346 @ $16 · Purchase (P): 233,654 @ $16 · +11 more | EDGAR |
| 2020-10-30 | 4 | SQZ Biotechnologies Co (SQZ) | Grant/award (A): 7,055 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1438226 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs